Global distribution Sedia Biosciences recently secured a co-exclusive distribution agreement with Thermo Fisher Scientific for AgriSeq products, expanding its global reach and creating a channel that could be leveraged to cross-sell HIV diagnostics, point-of-care tests, and related molecular tools to a broader customer base.

World Health WHO Pre-Qualification for the Asanté HIV-1/2 Oral Fluid Test positions Sedia as a credible supplier for international public health programs, highlighting opportunities to engage with governments, NGOs, and procurement agencies seeking approved HIV diagnostic solutions.

R&D & Services Sedia’s portfolio spans rapid point-of-care diagnostics, novel HIV incidence assays, and remote specimen collection devices, presenting upsell potential to current customers through bundled offerings, expanded test menus, and services like Sedia COVID-19 WGS for surveillance and outbreak response.

Quality & Compliance ISO 13485 certification and a focus on in vitro diagnostics manufacturing underscore reliability and regulatory readiness, enabling targeting of healthcare providers and distributors that prioritize compliant, quality-assured HIV and diagnostic products.

Growth & Partnerships With recent leadership in epidemiological assays and a distribution partnership, there are opportunities to pursue co-development, licensing, or exclusive regional partnerships, alongside expanding into remote testing workflows and workflow integration with existing lab customers.